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Abstract
Background. Sarcoidosis is associated with an increase in the number of alveolar T cells (CD3
  cells) and an increase of the
CD3
 CD4
  lymphocyte subset. However, the number of lymphocytes and the CD4/CD8 ratio in bronchoalveolar lavage
(BAL) fluid are highly variable in sarcoidosis. Comparative studies have demonstrated that geographic and ethnic factors
are linked to the specific characteristics of patients with sarcoidosis.
Aim of the study. To investigate peculiarities of BAL fluid (BALF) cell patterns in different clinical activity of pulmonary
sarcoidosis at the time of diagnosis.
Material and methods. A total of 308 non-treated patients (138 asymptomatic and 170 with sarcoidosis-related symptoms)
and 40 previously empirically steroid-treated patients with newly diagnosed sarcoidosis have been prospectively examined.
Results. Significant BAL fluid lymphocytosis and increased CD4/CD8 ratio were characteristic for all three sarcoidosis
patient groups. A total of 12% of asymptomatic patients, 3% of patients with sarcoidosis-related symptoms, and 5% of
previously treated symptomatic patients had normal BALF cell counts. Non-treated patients with sarcoidosis-related
symptoms had significantly higher lymphocytosis (45919% versus 39917%, PB0.01), CD4/CD8 ratio (9.395.0 versus
5.794.5, PB0.001), and total BALF cell count (4119322 10
6/mL versus 3349273 10
6/mL, PB0.05), compared with
asymptomatic patients. However, previously treated symptomatic patients had lower lymphocytosis (39915% versus 459
19%, P 0.058), and total BALF cell count (2929166 10
6/mL versus 4119322 10
6/mL, PB0.05) compared with non-
treated symptomatic patients. The same trend was noticed for CD4/CD8 ratio (8.394.8), although a statistically significant
difference was not achieved.
Conclusions. Independently of clinical symptoms at the time of diagnosis sarcoid patients have significantly different BAL
fluid cell patterns compared to healthy persons. BAL fluid cell changes are more prominent in corticosteroid non-treated
patients with clinically active sarcoidosis. Treatment with systemic corticosteroids may modify typical BALF cellular
patterns of sarcoidosis.
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Introduction
Sarcoidosis is a systemic granulomatous disease of
unknown aetiology that primarily affects the lungs,
although multiorgan involvement frequently occurs.
It is likely that the expression of the disorder in
response to inciting agent or agents is modified by
the genetics of the host immune response. Although
many clinical features and associated syndromes
have been described, the phenotype of sarcoidosis
at the time of diagnosing provides only limited
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the disorder (1). Sarcoidosis is the most frequently
observed interstitial lung disease of unknown origin.
The clinical manifestations are largely non-specific,
as are the histological features (2,3). The clinical
features of sarcoidosis are varied, but at either end of
the range they are an acute form (Lo ¨fgren’s syn-
drome) and chronic sarcoidosis (4).
Sarcoidosis is associated with an increase in the
number of alveolar T cells, and a shift to an increase
in CD4 cells within these cells can be observed (5).
Bronchoalveolar lavage (BAL) is a method of
sampling fluid and cells from a large area of the
lung tissue by instilling and aspirating saline via a
bronchoscope wedged in bronchi (4). The increase
in BAL lymphocytes and the CD4/CD8 ratio of
BAL lymphocytes is a typical feature of sarcoidosis
(6). However, the number of lymphocytes as well as
the CD4/CD8 ratio in BAL fluid (BALF) are highly
variable in sarcoidosis (7).
Comparative epidemiological studies have de-
monstrated that geographic, ethnic, and genetic
factors are linked to the specific clinical character-
istics of sarcoid patients (8 10).
The present study aimed to investigate peculia-
rities of BALF cell patterns in different clinical
activity of pulmonary sarcoidosis at the time of
diagnosis in a large group of sarcoid patients (n 
348). Only a few studies (11,12) were devoted to this
issue. In some of them (13) the number of subjects
was small. This is the first study designed to evaluate
this problem among the Lithuanian population.
Additionally, in this study the data from BALF cell
examinations in corticosteroid-treated and non-trea-
ted patients with sarcoidosis were compared. To our
knowledge such a study has not been published
earlier.
Material and methods
This is a prospective study of patients with a newly
diagnosed sarcoidosis. It is a part of the first large
sarcoidosis study in Lithuania launched in 1993.
The patients underwent diagnostic tests only as part
of routine clinical investigation. The study popula-
tion consisted of 348 sarcoid patients. The patients
were separated into three groups. The first group
consisted of 138 asymptomatic non-treated patients;
the second group consisted of 170 non-treated
patients who had sarcoidosis-related, mostly Lo ¨fg-
ren’s syndrome symptoms; and the third group (a
subgroup of the symptomatic patients) consisted of
40 patients who had been previously empirically
steroid-treated in other institutions (1 3 weeks, 20 
30 mg daily of prednisone or its equivalent) mainly
because of erythema nodosum and joint pains. All of
them visited the Centre of Pulmonology and Aller-
gology of Vilnius University Hospital Santaris ˇkiu ˛
klinikos in the period of 1995 to 2007. Sarcoidosis
was diagnosed according to World Association of
Sarcoidosis and Other Granulomatous Diseases
(WASOG) guide-lines (14).
None of the patients had any relevant medical
history or comorbidity (e.g. tuberculosis). No pa-
tient had a history of exposure to organic or mineral
dust that is known to cause granulomatous lung
disease. The demographic data of the study popula-
tion are summarized in Table I.
The control group consisted of 55 healthy
volunteers (35 non-smokers and 20 smokers). A
signed informed consent form was obtained from all
participants. The study has been approved by the
Committee on Biomedical Ethics of the Vilnius
University Hospital Santaris ˇkiu ˛ klinikos.
Fibre-optic bronchoscopy and BAL were per-
formed as described elsewhere (15). The subjects
Table I. Demographic data of the study patient population.
Demographics Asymptomatic Symptomatic Treated
Subjects, n 138 170 40
Age, years 35993 8 911 39910
Male/female, n 79/59 45/125 12/28
Non-smokers/smokers 106/32 145/25 36/4
FVC,% predicted 101915 105916 105916
FEV1,% predicted 99917 100915 100916
FEV1/FVC 81998 1 978 2 98
VC,% predicted 102916 106916 108913
TLC,% predicted 97911 96914 100912
DLCO,% predicted 88912 86915 85916
Data are presented as mean9standard deviation, and numbers (n).
FVC forced vital capacity; FEV1 forced expiratory volume in one second; VC vital capacity; TLC total lung capacity; DLCO 
diffusing capacity of carbon monoxide.
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delivered topically via an atomizer. The broncho-
scope was inserted transnasally (in most cases) or
orally and passed to segmental or subsegmental
bronchi. BAL was performed in the right middle
lobe, lingual, or in the area of greatest radiological
abnormality. Sterile isotonic saline at room tempera-
ture was instilled in two 50 mL aliquots. Each
aliquot was retrieved with gentle manual aspiration.
Only the second aliquot was analysed. We have used
the same BAL as well as BALF analysis method all
through the period of the study.
BALF cells were examined at the Laboratory of
Clinical Immunology at the Centre of Laboratory
Diagnostics of Vilnius University Hospital Santar-
is ˇkiu ˛ klinikos. BALF for cell analysis was filtered
through a 70 mm pore filter to remove mucus, and
then cellular material was sedimented by centrifuga-
tion (300 g for 10 min at 48C). Differential cell
counts of 600 BALF cells were performed on May-
Grunwald-Giemsa or similar stained preparations.
Viability of BALF cells was determined by 0.4%
trypan blue dye exclusion (this method is based on
the principle that live cells do not take up certain
dyes, whereas dead cells do). For lymphocyte sub-
population analysis 100 mL of cell suspensions (1 
10
6 cells) were incubated for 15 min at 48C with 20
mL fluorescein isothiocyanate (FITC) or phycoery-
thrin (PE) conjugated monoclonal antibody (Becton
Dickinson). Following the incubation, 2 mL of cold
phosphate buffered saline (PBS) was added to the
pellet and washed at 300 g for 10 min at 48C.
Prepared BALF samples were examined by flow
cytometry (FACS Calibur, Becton Dickinson).
Statistical methods
Statistical data were processed at the Department of
Mathematical Statistics of Vilnius Gediminas Tech-
nical University. Statistical data processing was
performed by SPSS 15.0 Program. The data of
different groups were compared according to Stu-
dent’s t test and Mann-Whitney U-test. Correlation
was evaluated by the Pearson correlation coefficient.
In all tests a P-value of B0.05 was considered to be
statistically significant.
Results
The volume of recovered BAL fluid was 65910 mL.
The percentage of the viability of the bronchoalveolar
lavage fluid cells was 9793%. Significant BAL fluid
lymphocytosis and increased CD4/CD8 ratio were
characteristic for all three sarcoidosis patient groups
(Table II). Normal (near-normal) BAL fluid cell
percentages were found in a minority of the patients.
Normal BALF cell counts were found in 12% of
asymptomaticpatients(Figure1),3%ofpatientswith
sarcoidosis-related symptoms (Figure 2), and 5% of
previously treated symptomatic patients (Figure 3).
Macrophage-lymphocyte rosettes (adherence of
lymphocytestoalveolarmacrophages)andLanghans-
type multinucleated giant cells were observed in
BALF of all patient groups, but not in healthy
volunteers’ BALF samples. Macrophage-lymphocyte
rosettes were found in 64%, 72%, and 75% of
asymptomatic patients, patients with symptoms, and
treated patients, respectively, and Langhans-type
giant cells in 7%, 15%, and 10% of cases respectively.
Table II. Characteristics of bronchoalveolar lavage ﬂuid (BALF) cell counts of patients and healthy volunteers.
Cells Healthy (n 55) Asymptomatic (n 138) Symptomatic (n 170) Treated (n 40)
Total cells ( 10
6/mL) 2549247 3349273
f 4119322
b 2929166
f
Macrophages, % 7998
a 56.4917
e 49.3920 55.5915
Lymphocytes, % 15.797
a 39917
e 45919 39915
Neutrophils, % 5924 945 955 93
Eosinophils, % 0.3904 0.691
c 0.790.9
a 0.590.7
c
CD4, % 44913
a 72915
d 82913 80912
CD8, % 32913
a 1798
d 12971 3 97
CD4/CD8 1.791.0
a 5.794.5
d 9.395.0 8.394.8
Data are presented as mean9standard deviation. The comparison was done for the three patient groups separately.
a PB0.001 healthy volunteers versus patients.
b PB0.01 healthy volunteers versus patients.
c PB0.05 healthy volunteers versus patients.
d PB0.001 symptomatic non-treated patients versus other patients.
e PB0.01 symptomatic non-treated patients versus other patients.
f PB0.05 symptomatic non-treated patients versus other patients.
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symptoms had significantly higher lymphocytosis
and CD4/CD8 ratios as well as total BALF cell
count and giant cells in BALF, compared with
asymptomatic patients. However, previously treated
symptomatic patients had lower lymphocytosis (P 
0.058) and total BALF cell count, compared with
non-treated symptomatic patients. The same trend
was seen for CD4/CD8 ratios, although statistically
significant difference was not achieved.
Evaluating sarcoid patients, a weak negative
correlation was observed comparing the presence of
symptoms of acute sarcoidosis (Lo ¨fgren’s syndrome)
with BALF neutrophils (r  0.26, PB0.001) and
eosinophils (r  0.27, PB0.001). Furthermore,
BAL fluid neutrophils and eosinophils correlated
negatively*weakly but statistically significantly*
with pulmonary function indices. Neutrophils corre-
lated with forced vital capacity (FVC) and vital
capacity (VC) (both r  0.26, PB0.05) and forced
expiratory volume in one second (FEV1)/FVC (r 
 0.24, PB0.05), and eosinophils with FVC (r  
0.26, PB0.05), FEV1 (r  0.3, PB0.01), and VC
(r  0.3, PB0.05) in asymptomatic patients. Neu-
trophils correlated with FVC (r  0.32, PB0.001),
VC (r  0.27, PB0.01), and FEV1 (r  0.33,
PB0.001), and eosinophils with FVC (r  0.26,
PB0.01), VC (r  0.28, PB0.01), and total lung
capacity (TLC) (r  0.32, PB0.01) in sympto-
matic patients.
Discussion
This study evaluated the bronchoalveolar lavage fluid
cells in different clinical activity of pulmonary sarcoi-
dosis at the time of diagnosis. Data of examination of
BALF cells of corticosteroid treated and non-trea-
ted patients with sarcoidosis were compared.
The major findings in our study are: 1) indepen-
dentlyofpresenceofclinicalsymptoms,asignificantly
increased number of BAL fluid lymphocytes and an
increased ratio of CD4/CD8 T cells compared with
healthy subjects were found; 2) patients with sarcoi-
dosis-related clinical symptoms had significantly
higher BAL fluid lymphocytes count and CD4/CD8
ratio compared with asymptomatic patients; 3) the
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Figure 1. Distribution of CD4/CD8 ratio in bronchoalveolar
lavage ﬂuid (BALF) of asymptomatic sarcoid patients.
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Figure 2. Distribution of CD4/CD8 ratio in bronchoalveolar
lavage ﬂuid (BALF) of sarcoid patients with clinical symptoms.
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Figure 3. Distribution of CD4/CD8 ratio in bronchoalveolar
lavage ﬂuid (BALF) of previously treated sarcoid patients with
clinical symptoms.
BAL in sarcoidosis 29number of BALF total cells and lymphocytes of
patients previously treated with systemic corticoster-
oids was lower compared with non-treated patients.
Key findings of our study*an increased number
of BALF lymphocytes and CD4/CD8 ratio among
the Lithuanian population*are in line with previous
publications (12,16). Changes of BALF cells reflect
populations of immune cells accumulated in the lung
parenchyma. Sarcoidosis is a granulomatous disorder
resulting from an uncontrolled cell-mediated im-
mune reaction characterized by accumulation of
activated monocytes/macrophages and CD4 T lym-
phocytesinallsitesofdiseaseactivity.Inthelung,this
accumulation in both air spaces and interstitium
(alveolitis) precedes and accompanies the develop-
ment of granulomas (17). The majority of our
patients had macrophage-lymphocyte rosettes and
Langhans-type giant cells in the BAL fluid. These
cells reflected lung parenchyma granulomas (18),
structured masses composed of macrophage-derived
cells (which assume an epithelioid aspect) and of
lymphocytes (19).
We have found that the clinical symptoms of our
study patients are associated with changes of BAL
fluid cell populations. Similar to our findings,
Valeyre et al. (13) found a large increase in the
percentage of lymphocytes in BAL fluid of sarcoid
patients with Lo ¨fgren’s syndrome, and Drent et al.
(12) identified that patients with erythema nodosum
and/or arthralgia and hilar lymphadenopathy have
the highest CD4/CD8 ratio compared with other
sarcoid patients. Ward et al. (11) found that the
lavage T lymphocytes percentage and CD4/CD8
ratio were highest in patients with sarcoidosis
studied soon after an acute onset with an inflamma-
tory condition such as erythema nodosum or uveitis.
A variability of BALF cell populations in every
group of patients was found. As shown in Figure 1
and Figure 2, the variability was higher in the group
of asymptomatic patients. A CD4/CD8 ratio  3.5,
which is a breaking-point for sarcoidosis differential
diagnostics (20), was found in a much greater part of
patients with sarcoidosis-related symptoms com-
pared to asymptomatic patients. Furthermore, sig-
nificantly more asymptomatic patients had normal
BALF cell percentages. The explanation of this
phenomenon may be different at the time of the
beginning of the disease. The time point of the onset
of the disease for the individual patient, with the
exception of patients with Lo ¨fgren’s syndrome, is
generally not known. It is likely that the duration of
the disorder for a substantial part of asymptomatic
patients in our study group was at least several
months. However, it seems that the disorder had not
continued for one year, as the number of neutrophils
and/or eosinophils in BALF was not high. Other
authors (21,22) have indicated that an elevated
count of these cells in BAL fluid is associated with
more advanced and severe sarcoidosis, although
markers for disease progression to fibrosis are
lacking (23). We have found previously a significant
decrease of BAL fluid CD4/CD8 ratio with increas-
ing radiographic stage of sarcoidosis (24).
Macrophage-lymphocyte rosettes and giant cells
(elements of immune granuloma) were found more
often in BALF of both symptomatic patient groups
compared to asymptomatic patients. This finding
may reflect still on-going inflammation in the lung
parenchyma. Macrophages and T lymphocytes from
sarcoid patients are activated, and they release
several mediators which recruit other immune cells
to the lung parenchyma (19). It is suggested that
apoptosis (programmed cell death) may be asso-
ciated with the course of granulomatous inflamma-
tion in pulmonary sarcoidosis (25). These processes
depend on various, mostly unknown, genetic and
environmental factors simultaneously (26,27). The
influence of ethnic and genetic factors determines
the heterogeneous clinical course of sarcoidosis (17).
Milder signs of active alveolitis (e.g. total cell
count, number of lymphocytes) in BAL fluid of
treated patients compared to non-treated patients
were found. Corticosteroids suppress the granuloma
formation and reverse consecutive clinical, radio-
graphical, functional and biological manifestations.
However, corticosteroid therapy is not curative and
seems not effective for the natural course of the
disease (17). We do not agree with the still occurring
practice of empirical treatment with corticosteroids
of patients with possible sarcoidosis. As our data
show, BAL fluid cell patterns may become non-
typical for sarcoidosis in such cases, and further
diagnostics may be complicated.
Conclusions
1. Independently of clinical symptoms at the
time of diagnosis sarcoid patients have sig-
nificantly different BAL fluid cell patterns
compared to healthy persons.
2. BAL fluid cell changes are more prominent
for corticosteroid non-treated patients with
clinically active sarcoidosis.
3. Treatment with systemic corticosteroids may
modify typical BALF cellular patterns of
sarcoidosis.
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